Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T.O.P.S. - Nevirapine and Combivir for pMTCT Resistance
NCT00144183Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2003
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lamivudine + zidovudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Boehringer Ingelheim. Started Jan 2003; status: completed.
02
Drugs
lamivudine + zidovudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00144183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144183.